Cannabinoid receptor-interacting protein Crip1a modulates CB1 receptor signaling in mouse hippocampus
- 739 Downloads
The cannabinoid type 1 receptor (Cnr1, CB1R) mediates a plethora of physiological functions in the central nervous system as a presynaptic modulator of neurotransmitter release. The recently identified cannabinoid receptor-interacting protein 1a (Cnrip1a, CRIP1a) binds to the C-terminal domain of CB1R, a region known to be important for receptor desensitization and internalization. Evidence that CRIP1a and CB1R interact in vivo has been reported, but the neuroanatomical distribution of CRIP1a is unknown. Moreover, while alterations of hippocampal CRIP1a levels following limbic seizures indicate a role in controlling excessive neuronal activity, the physiological function of CRIP1a in vivo has not been investigated. In this study, we analyzed the spatial distribution of CRIP1a in the hippocampus and examined CRIP1a as a potential modulator of CB1R signaling. We found that Cnrip1a mRNA is co-expressed with Cnr1 mRNA in pyramidal neurons and interneurons of the hippocampal formation. CRIP1a protein profiles were largely segregated from CB1R profiles in mossy cell terminals but not in hippocampal CA1 region. CB1R activation induced relocalization to close proximity with CRIP1a. Adeno-associated virus-mediated overexpression of CRIP1a specifically in the hippocampus revealed that CRIP1a modulates CB1R activity by enhancing cannabinoid-induced G protein activation. CRIP1a overexpression extended the depression of excitatory currents by cannabinoids in pyramidal neurons of the hippocampus and diminished the severity of chemically induced acute epileptiform seizures. Collectively, our data indicate that CRIP1a enhances hippocampal CB1R signaling in vivo.
KeywordsCannabinoid receptor-interacting protein 1a CRIP1a Hippocampus Cannabinoid receptor CB1R Seizures AAV
This work was supported by the Deutsche Forschungsgemeinschaft FOR926 (subprojects SP3 to B. L. and K. M.), SFB 1080 (subprojects A1 to H. J. L. and B8 to B. L.), the Australian Research Council (ARC Future Fellowship to M. K.), the Hungarian Brain Research Program, KTIA_NAP_13-2-2014-0013 (to A.A.), the Swedish Medical Research Council and the Novo Nordisk Foundation (T. H.). We thank Ruth Jelinek for excellent help with vector production; Erik Keimpema and Klaudia Barabas for input at early stages of the manuscript; Ken Mackie and Deborah Lewis for the CRIP1a antibodies and the rat Cnrip1a cDNA.
Conflict of interest
The authors declare that they have no conflict of interest.
- Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26(11):2991–3001. doi: 10.1523/JNEUROSCI.4872-05.2006 CrossRefPubMedGoogle Scholar
- Keimpema E, Barabas K, Morozov YM, Tortoriello G, Torii M, Cameron G, Yanagawa Y, Watanabe M, Mackie K, Harkany T (2010) Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. J Neurosci 30(42):13992–14007. doi: 10.1523/JNEUROSCI.2126-10.2010 CrossRefPubMedPubMedCentralGoogle Scholar
- Ludanyi A, Eross L, Czirjak S, Vajda J, Halasz P, Watanabe M, Palkovits M, Magloczky Z, Freund TF, Katona I (2008) Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 28(12):2976–2990. doi: 10.1523/JNEUROSCI.4465-07.2008 CrossRefPubMedGoogle Scholar
- Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302(5642):84–88. doi: 10.1126/science.1088208 CrossRefPubMedGoogle Scholar
- Mikasova L, Groc L, Choquet D, Manzoni OJ (2008) Altered surface trafficking of presynaptic cannabinoid type 1 receptor in and out synaptic terminals parallels receptor desensitization. Proc Natl Acad Sci USA 105(47):18596–18601. doi: 10.1073/pnas.0805959105 CrossRefPubMedPubMedCentralGoogle Scholar
- Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51(4):455–466. doi: 10.1016/j.neuron.2006.07.006 CrossRefPubMedPubMedCentralGoogle Scholar
- Niehaus JL, Liu Y, Wallis KT, Egertova M, Bhartur SG, Mukhopadhyay S, Shi S, He H, Selley DE, Howlett AC, Elphick MR, Lewis DL (2007) CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol Pharmacol 72(6):1557–1566. doi: 10.1124/mol.107.039263 CrossRefPubMedGoogle Scholar
- Smith TH, Blume LC, Straiker A, Cox JO, David BG, McVoy JS, Sayers KW, Poklis JL, Abdullah RA, Egertova M, Chen CK, Mackie K, Elphick MR, Howlett AC, Selley DE (2015) Cannabinoid receptor interacting protein 1a (CRIP1a) modulates CB1 receptor signaling and regulation. Mol Pharmacol. doi: 10.1124/mol.114.096495 Google Scholar
- Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, Watanabe M (2006) Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 26(18):4740–4751. doi: 10.1523/JNEUROSCI.0054-06.2006 CrossRefPubMedGoogle Scholar